Down another 6% in a week! So will the GSK share price ever recover?
The GSK share price has had a rotten few years and now it's heading south yet again. Investor Harvey Jones continues to hang ...
GSK (LSE:GSK) Poised for Growth with Strong Sales, Strategic Alliances, and New Vaccine Launches
GSK(LSE:GSK) is navigating a dynamic environment marked by both opportunities and challenges. Recent highlights include a ...
GlaxoSmithKline Sell Rating Justified by Earnings Concerns and Market Challenges
Bank of America Securities analyst Graham Parry maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) yesterday and set a ...
GlaxoSmithKline (GSK) Gets a Sell from J.P. Morgan
J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...
Moderna: Still Bullish View
Moderna should not be left off the list of interesting investment opportunities, as the company has one of the best pipelines ...
GSK's Respiratory Syncytial Virus Vaccine Given Together With Shingles Shot Shows Non-Inferior Immune Response In Older Adults
GSK plc (NYSE:GSK) released topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, ...
Ideaya Biosciences Advances Synthetic Lethality With IDE397 Success
IDEAYA Biosciences is a promising biotech company targeting genetic vulnerabilities in cancer cells with synthetic lethality.
AstraZeneca's Asthma Drug Gets FDA Approval For Rare Disease Of Blood Vessel Inflammation
The FDA has approved AstraZeneca's Fasenra for eosinophilic granulomatosis with polyangiitis based on Phase 3 MANDARA trial ...